Andre Zimerman, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cholesterol, VLDL | 1 | 2024 | 70 | 0.930 |
Why?
|
Oligonucleotides, Antisense | 2 | 2024 | 461 | 0.920 |
Why?
|
Triglycerides | 2 | 2024 | 2461 | 0.670 |
Why?
|
Tachycardia, Supraventricular | 1 | 2021 | 273 | 0.620 |
Why?
|
Science | 1 | 2020 | 239 | 0.590 |
Why?
|
Exercise Test | 3 | 2023 | 2127 | 0.530 |
Why?
|
Speech | 1 | 2021 | 554 | 0.530 |
Why?
|
Cholesterol | 1 | 2024 | 2905 | 0.490 |
Why?
|
Bullying | 1 | 2018 | 232 | 0.490 |
Why?
|
Automobile Driving | 1 | 2019 | 441 | 0.470 |
Why?
|
Heart Failure | 7 | 2023 | 11671 | 0.440 |
Why?
|
Electrocardiography | 5 | 2021 | 6377 | 0.440 |
Why?
|
Attitude | 1 | 2018 | 775 | 0.430 |
Why?
|
Myocardial Revascularization | 1 | 2016 | 790 | 0.390 |
Why?
|
Acute Coronary Syndrome | 3 | 2022 | 2190 | 0.350 |
Why?
|
Brazil | 5 | 2020 | 1230 | 0.340 |
Why?
|
Poverty | 1 | 2020 | 2697 | 0.310 |
Why?
|
Tachycardia, Ventricular | 1 | 2017 | 1304 | 0.310 |
Why?
|
Cardiomyopathies | 2 | 2017 | 1964 | 0.310 |
Why?
|
Suicidal Ideation | 1 | 2018 | 1447 | 0.300 |
Why?
|
Liver | 1 | 2023 | 7528 | 0.300 |
Why?
|
Heart Function Tests | 2 | 2016 | 318 | 0.250 |
Why?
|
Myocardial Infarction | 4 | 2022 | 11461 | 0.240 |
Why?
|
Catheter Ablation | 1 | 2017 | 2751 | 0.230 |
Why?
|
Angiopoietins | 1 | 2024 | 85 | 0.230 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2016 | 2751 | 0.220 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5127 | 0.190 |
Why?
|
Physicians | 1 | 2019 | 4591 | 0.190 |
Why?
|
Ventricular Function, Left | 4 | 2021 | 3879 | 0.190 |
Why?
|
Metoprolol | 1 | 2021 | 90 | 0.180 |
Why?
|
Ventricular Pressure | 1 | 2021 | 210 | 0.170 |
Why?
|
Anticoagulants | 1 | 2016 | 4812 | 0.170 |
Why?
|
Lipoproteins | 1 | 2024 | 881 | 0.170 |
Why?
|
Double-Blind Method | 4 | 2024 | 12341 | 0.160 |
Why?
|
Furosemide | 1 | 2019 | 170 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 771 | 0.160 |
Why?
|
Oxygen Consumption | 2 | 2023 | 1866 | 0.160 |
Why?
|
Peer Review, Research | 1 | 2022 | 340 | 0.160 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 152 | 0.150 |
Why?
|
Florida | 1 | 2019 | 431 | 0.150 |
Why?
|
Risk Assessment | 2 | 2016 | 23996 | 0.140 |
Why?
|
Atrial Premature Complexes | 1 | 2016 | 17 | 0.140 |
Why?
|
Down-Regulation | 1 | 2024 | 2919 | 0.140 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2021 | 774 | 0.140 |
Why?
|
Stroke Volume | 5 | 2023 | 5496 | 0.140 |
Why?
|
Endocardium | 1 | 2017 | 248 | 0.140 |
Why?
|
Middle Aged | 13 | 2024 | 220921 | 0.130 |
Why?
|
Prosthesis Implantation | 1 | 2020 | 592 | 0.130 |
Why?
|
Ventricular Premature Complexes | 1 | 2016 | 112 | 0.130 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2021 | 829 | 0.130 |
Why?
|
Lactic Acid | 1 | 2020 | 1139 | 0.120 |
Why?
|
Withholding Treatment | 1 | 2019 | 617 | 0.120 |
Why?
|
Shock, Cardiogenic | 1 | 2020 | 709 | 0.120 |
Why?
|
Humans | 26 | 2024 | 761596 | 0.120 |
Why?
|
Gold | 1 | 2017 | 482 | 0.110 |
Why?
|
Patient Admission | 1 | 2021 | 1367 | 0.110 |
Why?
|
Prognosis | 5 | 2023 | 29629 | 0.110 |
Why?
|
Male | 14 | 2024 | 360846 | 0.100 |
Why?
|
Vaccination | 2 | 2022 | 3384 | 0.100 |
Why?
|
Outpatients | 1 | 2020 | 1597 | 0.100 |
Why?
|
Death, Sudden, Cardiac | 2 | 2021 | 1555 | 0.100 |
Why?
|
Caffeine | 1 | 2016 | 700 | 0.100 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1723 | 0.100 |
Why?
|
Defibrillators, Implantable | 1 | 2021 | 1490 | 0.100 |
Why?
|
Pyridones | 1 | 2017 | 809 | 0.100 |
Why?
|
Cicatrix | 1 | 2017 | 798 | 0.100 |
Why?
|
Influenza, Human | 1 | 2022 | 1521 | 0.090 |
Why?
|
Mothers | 1 | 2021 | 2198 | 0.090 |
Why?
|
Coronary Artery Bypass | 1 | 2020 | 2188 | 0.090 |
Why?
|
Canada | 1 | 2016 | 2122 | 0.090 |
Why?
|
Female | 13 | 2024 | 392705 | 0.090 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1613 | 0.080 |
Why?
|
Adolescent Behavior | 1 | 2018 | 1190 | 0.080 |
Why?
|
Genetic Markers | 1 | 2016 | 2601 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2020 | 0.080 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 1462 | 0.080 |
Why?
|
Europe | 1 | 2016 | 3420 | 0.080 |
Why?
|
Peptide Fragments | 1 | 2020 | 5112 | 0.080 |
Why?
|
Central Nervous System Stimulants | 1 | 2016 | 1177 | 0.070 |
Why?
|
Chronic Disease | 1 | 2023 | 9319 | 0.070 |
Why?
|
Aged | 6 | 2024 | 169310 | 0.070 |
Why?
|
Stroke | 2 | 2022 | 9758 | 0.070 |
Why?
|
Ultrasonography | 1 | 2021 | 5971 | 0.070 |
Why?
|
Data Collection | 1 | 2017 | 3322 | 0.070 |
Why?
|
United States | 4 | 2021 | 72340 | 0.070 |
Why?
|
Time Factors | 3 | 2024 | 39969 | 0.070 |
Why?
|
Arrhythmias, Cardiac | 1 | 2016 | 2244 | 0.070 |
Why?
|
Pyrazoles | 1 | 2017 | 2009 | 0.070 |
Why?
|
Hemorrhage | 1 | 2017 | 3424 | 0.060 |
Why?
|
Survival Rate | 2 | 2016 | 12723 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2024 | 64685 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 7879 | 0.050 |
Why?
|
Patient Discharge | 1 | 2016 | 3443 | 0.050 |
Why?
|
Lung | 1 | 2021 | 10002 | 0.050 |
Why?
|
Vaccines, Inactivated | 1 | 2022 | 179 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39106 | 0.050 |
Why?
|
Adult | 5 | 2023 | 221210 | 0.050 |
Why?
|
Oxygenators, Membrane | 1 | 2020 | 56 | 0.050 |
Why?
|
Incidence | 2 | 2016 | 21355 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.040 |
Why?
|
New York | 1 | 2023 | 874 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10212 | 0.040 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2021 | 198 | 0.040 |
Why?
|
Risk Factors | 4 | 2021 | 74213 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 551 | 0.040 |
Why?
|
Diastole | 1 | 2021 | 782 | 0.040 |
Why?
|
Body Fluids | 1 | 2019 | 320 | 0.040 |
Why?
|
Protein Precursors | 1 | 2020 | 1132 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2021 | 1119 | 0.030 |
Why?
|
Safety | 1 | 2019 | 1149 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2021 | 80647 | 0.030 |
Why?
|
Systole | 1 | 2016 | 936 | 0.030 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2016 | 578 | 0.030 |
Why?
|
Self Concept | 1 | 2019 | 1045 | 0.030 |
Why?
|
Dyspnea | 1 | 2019 | 1347 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 14665 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2016 | 710 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2017 | 1475 | 0.020 |
Why?
|
Prospective Studies | 3 | 2021 | 54423 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2079 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1242 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5247 | 0.020 |
Why?
|
Adolescent | 1 | 2018 | 88326 | 0.020 |
Why?
|
Heart-Assist Devices | 1 | 2020 | 1287 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10090 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20100 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12463 | 0.020 |
Why?
|
Myocardial Ischemia | 1 | 2016 | 2113 | 0.020 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2118 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10766 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15266 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3688 | 0.010 |
Why?
|
Genetic Testing | 1 | 2016 | 3537 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10508 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22176 | 0.010 |
Why?
|
Blood Pressure | 1 | 2016 | 8481 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14608 | 0.010 |
Why?
|
Prevalence | 1 | 2016 | 15733 | 0.010 |
Why?
|
Algorithms | 1 | 2016 | 14033 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 58984 | 0.010 |
Why?
|
Child | 1 | 2021 | 80158 | 0.010 |
Why?
|